Pulmonx Corp. (LUNG): Price and Financial Metrics
LUNG Price/Volume Stats
| Current price | $6.20 | 52-week high | $14.84 |
| Prev. close | $6.00 | 52-week low | $5.46 |
| Day low | $5.86 | Volume | 179,300 |
| Day high | $6.22 | Avg. volume | 389,308 |
| 50-day MA | $7.13 | Dividend yield | N/A |
| 200-day MA | $7.92 | Market Cap | 244.83M |
LUNG Stock Price Chart Interactive Chart >
Pulmonx Corp. (LUNG) Company Bio
Pulmonx Corp. provides interventional pulmonology, planning tools, and treatments for obstructive lung diseases. It carries out its operations in the following geographical locations: Europe, Middle East and Africa (EMEA), Asia Pacific, Other International, and United States. It offers the Zephyr Endobronchial Valve, an implantable device used to occlude all airways feeding the hyperinflated lobe of a lung that is most diseased with emphysema. It also offers StratX Lung Analysis, a platform designed to treat severe emphysema, and the Chartis Assessment System, a pulmonary assessment system. The company was founded by Rodney C. Perkins and is headquartered in Redwood City, CA.
LUNG Price Returns
| 1-mo | 1.14% |
| 3-mo | -17.44% |
| 6-mo | -23.17% |
| 1-year | -41.51% |
| 3-year | -82.39% |
| 5-year | N/A |
| YTD | -51.37% |
| 2023 | 51.25% |
| 2022 | -73.71% |
| 2021 | -53.54% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...